Pharma Stocks Outlook for the week – 10 to 14.07.2017
Pharma Stocks Outlook for the week – 10 to 14.07.2017
( www.rupeedesk.in )
The shares of pharmaceutical companies are likely to rise next week, as weakness in the sector is
seen factored into the stocks. However, the gains may be limited because investors may remain
cautious ahead of the announcement of corporate earnings for the June quarter. Most of the stocks have bottomed out now. But people may wait for companies to report their earnings before taking fresh position. The companies in the sector, the revenue for Apr-Jun is expected to remain flat on year due to a high base. However, operating income and bottomline are expected to decline 16% and 26%, respectively, on account of a sharp appreciation in the rupee. Even on the domestic front, sales are expected to decline by mid-single digit for the quarter because of the disruption caused by de-stocking as a result of the goods and services tax implementation. On the other hand, weak sales of generics of Gleevec and Glumetza are seen weighing on the earning of Sun Pharmaceutical Industries and Lupin, respectively.
Source : Cogencis Information Services Ltd.
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Free Commodity Tips : Join our Whatsapp No : 9094047040
Pharma Stocks Outlook for the week – 10 to 14.07.2017
( www.rupeedesk.in )
The shares of pharmaceutical companies are likely to rise next week, as weakness in the sector is
seen factored into the stocks. However, the gains may be limited because investors may remain
cautious ahead of the announcement of corporate earnings for the June quarter. Most of the stocks have bottomed out now. But people may wait for companies to report their earnings before taking fresh position. The companies in the sector, the revenue for Apr-Jun is expected to remain flat on year due to a high base. However, operating income and bottomline are expected to decline 16% and 26%, respectively, on account of a sharp appreciation in the rupee. Even on the domestic front, sales are expected to decline by mid-single digit for the quarter because of the disruption caused by de-stocking as a result of the goods and services tax implementation. On the other hand, weak sales of generics of Gleevec and Glumetza are seen weighing on the earning of Sun Pharmaceutical Industries and Lupin, respectively.
Source : Cogencis Information Services Ltd.
